RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
GenScript Biotech, a biologics CDMO, has completed construction of its R&D and production center in Nanjing. When fully operational, the center will offer a full end-to-end suite of biological services, starting with pre-clinical research, and continuing into commercial production. The company’s biologics GMP production center, which is expected to start production in 2020, will have 2,600 liters of capacity, enough for Phase I and II clinical supply. GenScript has a well-established global business that supplies custom synthesized genes for research. Source: China Biotoday
